Pharmaceutical - Novo Nordisk, Biosimilars

Filter

Current filters:

Novo NordiskBiosimilars

Popular Filters

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

26-06-2014

The imminent patent expiration of French pharma major Sanofi’s Lantus (insulin glargine) has opened…

BiosimilarsDiabetesdulaglutideEli LillyIDegLiraLantusLixiLanMarkets & MarketingNovo NordiskPharmaceuticalResearchSanofiToujeo

Company Spotlight

ImmunoGen

ImmunoGen

Back to top